443 related articles for article (PubMed ID: 11779040)
1. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
Naidu PS; Kulkarni SK
Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
[TBL] [Abstract][Full Text] [Related]
2. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Haleem DJ; Samad N; Haleem MA
Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
[TBL] [Abstract][Full Text] [Related]
3. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide.
Naidu PS; Kulkarni SK
Behav Pharmacol; 2001 Jun; 12(3):209-16. PubMed ID: 11485057
[TBL] [Abstract][Full Text] [Related]
4. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists.
Naidu PS; Kulkarni SK
Eur J Pharmacol; 2001 May; 420(2-3):113-7. PubMed ID: 11408032
[TBL] [Abstract][Full Text] [Related]
5. Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats.
Creed-Carson M; Oraha A; Nobrega JN
Behav Brain Res; 2011 Jun; 219(2):273-9. PubMed ID: 21262266
[TBL] [Abstract][Full Text] [Related]
6. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
Singh A; Naidu PS; Kulkarni SK
Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
[TBL] [Abstract][Full Text] [Related]
7. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.
Naidu PS; Singh A; Kulkarni SK
Br J Pharmacol; 2002 May; 136(2):193-200. PubMed ID: 12010767
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
9. Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors.
Bishnoi M; Chopra K; Kulkarni SK
Psychopharmacology (Berl); 2008 Feb; 196(2):243-54. PubMed ID: 17955214
[TBL] [Abstract][Full Text] [Related]
10. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia.
Naidu PS; Singh A; Kulkarni SK
Neuropharmacology; 2003 Jun; 44(8):1100-6. PubMed ID: 12763102
[TBL] [Abstract][Full Text] [Related]
11. Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia.
Bachus SE; Yang E; McCloskey SS; Minton JN
Behav Brain Res; 2012 Jun; 231(2):323-36. PubMed ID: 22503783
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation.
Datta S; Jamwal S; Deshmukh R; Kumar P
Eur J Pharmacol; 2016 Jan; 771():229-35. PubMed ID: 26712377
[TBL] [Abstract][Full Text] [Related]
13. The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats.
Ellenbroek BA; Prinssen EP; Cools AR
Eur J Neurosci; 1994 Jan; 6(1):1-8. PubMed ID: 7907518
[TBL] [Abstract][Full Text] [Related]
14. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
Schreiber R; Brocco M; Audinot V; Gobert A; Veiga S; Millan MJ
J Pharmacol Exp Ther; 1995 Apr; 273(1):101-12. PubMed ID: 7714755
[TBL] [Abstract][Full Text] [Related]
15. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
[TBL] [Abstract][Full Text] [Related]
16. Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia.
Samad N; Khan A; Perveen T; Haider S; Abdul Haleem M; Haleem DJ
Acta Neurobiol Exp (Wars); 2007; 67(4):389-97. PubMed ID: 18320717
[TBL] [Abstract][Full Text] [Related]
17. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
Ninan I; Kulkarni SK
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905
[TBL] [Abstract][Full Text] [Related]
18. Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol.
Marchese G; Bartholini F; Ruiu S; Casti P; Casu GL; Pani L
Eur J Pharmacol; 2004 Jan; 483(1):65-9. PubMed ID: 14709327
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Methods Find Exp Clin Pharmacol; 2007 Apr; 29(3):211-6. PubMed ID: 17520104
[TBL] [Abstract][Full Text] [Related]
20. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
Bishnoi M; Kumar A; Chopra K; Kulkarni SK
Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
